Operative Time is Associated With Postoperative Complications After Pulmonary Lobectomy.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
01 12 2023
Historique:
medline: 9 11 2023
pubmed: 7 9 2022
entrez: 6 9 2022
Statut: ppublish

Résumé

To investigate the association between operative time and postoperative outcomes. The association between operative time and morbidity after pulmonary lobectomy has not been characterized fully. Patients who underwent pulmonary lobectomy for primary lung cancer at our institution from 2010 to 2018 were reviewed. Exclusion criteria included clinical stage ≥IIb disease, conversion to thoracotomy, and previous ipsilateral lung treatment. Operative time was measured from incision to closure. Relationships between operative time and outcomes were quantified using multivariable mixed-effects models with surgeon-level random effects. In total, 1651 patients were included. The median age was 68 years (interquartile range, 61-74), and 63% of patients were women. Median operative time was 3.2 hours (interquartile range, 2.7-3.8) for all cases, 3.0 hours for open procedures, 3.3 hours for video-assisted thoracoscopies, and 3.3 hours for robotic procedures ( P =0.0002). Overall, 488 patients (30%) experienced a complication; 77 patients (5%) had a major complication (grade ≥3), and 5 patients (0.3%) died within 30 days of discharge. On multivariable analysis, operative time was associated with higher odds of any complication [odds ratio per hour, 1.37; 95% confidence interval (CI), 1.20-1.57; P <0.0001] and major complication (odds ratio per hour, 1.41; 95% CI, 1.21-1.64; P <0.0001). Operative time was also associated with longer hospital length of stay (β, 1.09; 95% CI, 1.04-1.14; P =0.001). Longer operative time was associated with worse outcomes in patients who underwent lobectomy. Operative time is a potential risk factor to consider in the perioperative phase.

Sections du résumé

OBJECTIVE
To investigate the association between operative time and postoperative outcomes.
BACKGROUND
The association between operative time and morbidity after pulmonary lobectomy has not been characterized fully.
METHODS
Patients who underwent pulmonary lobectomy for primary lung cancer at our institution from 2010 to 2018 were reviewed. Exclusion criteria included clinical stage ≥IIb disease, conversion to thoracotomy, and previous ipsilateral lung treatment. Operative time was measured from incision to closure. Relationships between operative time and outcomes were quantified using multivariable mixed-effects models with surgeon-level random effects.
RESULTS
In total, 1651 patients were included. The median age was 68 years (interquartile range, 61-74), and 63% of patients were women. Median operative time was 3.2 hours (interquartile range, 2.7-3.8) for all cases, 3.0 hours for open procedures, 3.3 hours for video-assisted thoracoscopies, and 3.3 hours for robotic procedures ( P =0.0002). Overall, 488 patients (30%) experienced a complication; 77 patients (5%) had a major complication (grade ≥3), and 5 patients (0.3%) died within 30 days of discharge. On multivariable analysis, operative time was associated with higher odds of any complication [odds ratio per hour, 1.37; 95% confidence interval (CI), 1.20-1.57; P <0.0001] and major complication (odds ratio per hour, 1.41; 95% CI, 1.21-1.64; P <0.0001). Operative time was also associated with longer hospital length of stay (β, 1.09; 95% CI, 1.04-1.14; P =0.001).
CONCLUSIONS
Longer operative time was associated with worse outcomes in patients who underwent lobectomy. Operative time is a potential risk factor to consider in the perioperative phase.

Identifiants

pubmed: 36066195
doi: 10.1097/SLA.0000000000005696
pii: 00000658-202312000-00050
pmc: PMC9985664
mid: NIHMS1832497
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1259-e1266

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Références

Eur J Cardiothorac Surg. 2019 Dec 1;56(6):1097-1103
pubmed: 31408146
Ann Thorac Surg. 2008 Apr;85(4):1158-64; discussion 1164-5
pubmed: 18355489
Ann Thorac Surg. 2019 Dec;108(6):1648-1655
pubmed: 31400324
Ann Surg. 2005 Jun;241(6):879-82; discussion 882-4
pubmed: 15912037
J Surg Res. 2006 May 15;132(2):159-63
pubmed: 16412471
Ann Thorac Surg. 2008 Jan;85(1):231-5; discussion 235-6
pubmed: 18154816
J Cardiothorac Surg. 2018 Apr 12;13(1):28
pubmed: 29673386
Arch Surg. 2004 Apr;139(4):366-9; discussion 369-70
pubmed: 15078701
Chest. 2000 Nov;118(5):1263-70
pubmed: 11083673
Ann Thorac Surg. 2008 Feb;85(2):416-9
pubmed: 18222235
J Am Coll Surg. 2016 Jun;222(6):992-1000.e1
pubmed: 27118714
World J Surg. 2013 Nov;37(11):2561-8
pubmed: 23887596
J Am Coll Surg. 2010 Jan;210(1):60-5.e1-2
pubmed: 20123333
Surgeon. 2013 Jun;11(3):169-76
pubmed: 23490287
Eur J Anaesthesiol. 2001 Aug;18(8):540-7
pubmed: 11473561
Ann Thorac Surg. 2018 May;105(5):1469-1475
pubmed: 29501644
Ann Thorac Surg. 2021 Dec;112(6):1855-1861
pubmed: 33358890
Br J Anaesth. 2017 Mar 1;118(3):317-334
pubmed: 28186222
J Thorac Cardiovasc Surg. 1995 Feb;109(2):275-81; discussion 281-3
pubmed: 7853881
Chest. 2005 Oct;128(4):2647-52
pubmed: 16236938
J Thorac Cardiovasc Surg. 1999 Mar;117(3):581-6; discussion 586-7
pubmed: 10047663
Ann Thorac Surg. 2017 Apr;103(4):1092-1100
pubmed: 28109575
Ann Thorac Surg. 2014 Jan;97(1):236-42; discussion 242-4
pubmed: 24090577
Ann Thorac Surg. 2006 Mar;81(3):1013-9; discussion 1019-20
pubmed: 16488712
Ann Thorac Surg. 2017 Sep;104(3):1020-1026
pubmed: 28577845
J Thorac Cardiovasc Surg. 2009 Jul;138(1):11-8
pubmed: 19577048
Thorax. 2010 Sep;65(9):815-8
pubmed: 20805178
J Surg Res. 2015 Oct;198(2):441-9
pubmed: 25930169
J Thorac Dis. 2018 Nov;10(Suppl 32):S3761-S3772
pubmed: 30505563

Auteurs

Paolo de Angelis (P)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Kay See Tan (KS)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

Neel P Chudgar (NP)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Joseph Dycoco (J)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Prasad S Adusumilli (PS)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Manjit S Bains (MS)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Matthew J Bott (MJ)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Robert J Downey (RJ)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

James Huang (J)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

James M Isbell (JM)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Daniela Molena (D)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Bernard J Park (BJ)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Valerie W Rusch (VW)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Smita Sihag (S)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

David R Jones (DR)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Gaetano Rocco (G)

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH